Compugen Analyst Ratings
Compugen Analyst Ratings
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $13.00. The current price Compugen (CGEN) is trading at is $1.03, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 06/06/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | → Buy |
| 05/26/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/24/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/16/2023 | 579.61% | Oppenheimer | $8 → $7 | Maintains | Outperform |
| 02/28/2023 | 676.7% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 02/08/2023 | -51.46% | Jefferies | → $0.5 | Downgrades | Hold → Underperform |
| 01/05/2023 | 1162.14% | EF Hutton | → $13 | Initiates Coverage On | → Buy |
| 11/15/2022 | 676.7% | Oppenheimer | $12 → $8 | Maintains | Outperform |
| 08/23/2022 | 288.35% | Truist Securities | $14 → $4 | Maintains | Buy |
| 08/08/2022 | 288.35% | JMP Securities | $8 → $4 | Maintains | Market Outperform |
| 08/08/2022 | 1065.05% | Oppenheimer | $14 → $12 | Maintains | Outperform |
| 08/05/2022 | 94.17% | Jefferies | → $2 | Downgrades | Buy → Hold |
| 02/25/2022 | 1259.22% | Oppenheimer | $17 → $14 | Maintains | Outperform |
| 02/25/2022 | 773.79% | SVB Leerink | $16 → $9 | Maintains | Outperform |
| 04/06/2021 | 1453.4% | SVB Leerink | $19 → $16 | Maintains | Outperform |
| 08/19/2020 | 1744.66% | SVB Leerink | $15 → $19 | Maintains | Outperform |
| 05/13/2020 | 1744.66% | Stifel | → $19 | Initiates Coverage On | → Buy |
| 05/07/2020 | 1356.31% | SVB Leerink | → $15 | Initiates Coverage On | → Outperform |
| 04/22/2020 | 2618.45% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 03/24/2020 | 1453.4% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/21/2020 | 1162.14% | Cantor Fitzgerald | $10 → $13 | Reiterates | → Overweight |
| 01/16/2020 | 870.87% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 1162.14% | EF Hutton | →$13 | 重申 | 購買→購買 |
| 06/06/2023 | 1162.14% | EF Hutton | →$13 | 重申 | →購買 |
| 2023年05月26日 | 1162.14% | EF Hutton | →$13 | 重申 | 購買→購買 |
| 2023年05月24日 | 1162.14% | EF Hutton | →$13 | 重申 | 購買→購買 |
| 2023年05月16日 | 579.61% | 奧本海默 | $8→$7 | 維護 | 跑贏大盤 |
| 02/28/2023 | 676.7% | 奧本海默 | →$8 | 重申 | →跑贏大盤 |
| 02/08/2023 | -51.46% | 傑富瑞 | →$0.5 | 評級下調 | 持有→表現不佳 |
| 01/05/2023 | 1162.14% | EF Hutton | →$13 | 開始承保 | →購買 |
| 2022年11月15日 | 676.7% | 奧本海默 | $12→$8 | 維護 | 跑贏大盤 |
| 2022年08月23日 | 288.35% | Truist證券 | $14→$4 | 維護 | 買 |
| 2022/08/08 | 288.35% | JMP證券 | $8→$4 | 維護 | 市場表現強於大盤 |
| 2022/08/08 | 1065.05% | 奧本海默 | $14→$12 | 維護 | 跑贏大盤 |
| 08/05/2022 | 94.17% | 傑富瑞 | →$2 | 評級下調 | 購買→Hold |
| 02/25/2022 | 1259.22% | 奧本海默 | $17→$14 | 維護 | 跑贏大盤 |
| 02/25/2022 | 773.79% | SVB Leerink | $16→$9 | 維護 | 跑贏大盤 |
| 04/06/2021 | 1453.4% | SVB Leerink | $19→$16 | 維護 | 跑贏大盤 |
| 2020年08月19日 | 1744.66% | SVB Leerink | $15→$19 | 維護 | 跑贏大盤 |
| 2020/05/13 | 1744.66% | Stifel | →$19 | 開始承保 | →購買 |
| 05/07/2020 | 1356.31% | SVB Leerink | →$15 | 開始承保 | →跑贏大盤 |
| 04/22/2020 | 2618.45% | 羅斯資本 | →$28 | 開始承保 | →購買 |
| 03/24/2020 | 1453.4% | SunTrust Robinson Humphrey | →$16 | 開始承保 | →購買 |
| 02/21/2020 | 1162.14% | 康託·菲茨傑拉德 | $10→$13 | 重申 | →超重 |
| 1/16/2020 | 870.87% | 康託·菲茨傑拉德 | →$10 | 開始承保 | →超重 |
What is the target price for Compugen (CGEN)?
康柏(Compugen)的目標價是多少？
The latest price target for Compugen (NASDAQ: CGEN) was reported by EF Hutton on August 7, 2023. The analyst firm set a price target for $13.00 expecting CGEN to rise to within 12 months (a possible 1162.14% upside). 12 analyst firms have reported ratings in the last year.
英孚赫頓於2023年8月7日報道了康柏基因(納斯達克代碼：CGEN)的最新目標價。這家分析公司將目標價定為13美元，預計CGEN將在12個月內上漲至(可能上漲1162.14%)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Compugen (CGEN)?
Compugen(CGEN)的最新分析師評級是多少？
The latest analyst rating for Compugen (NASDAQ: CGEN) was provided by EF Hutton, and Compugen reiterated their buy rating.
科爾根(納斯達克代碼：CGEN)的最新分析師評級由EF Hutton提供，科爾根重申其買入評級。
When is the next analyst rating going to be posted or updated for Compugen (CGEN)?
Compugen(CGEN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compugen was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Compugen的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Compugen的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右提供。
Is the Analyst Rating Compugen (CGEN) correct?
分析師評級計算(CGEN)正確嗎？
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $13.00. The current price Compugen (CGEN) is trading at is $1.03, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Compugen(CGEN)評級被重申，目標價在0.00美元至13.00美元之間。Compugen目前的交易價格為1.03美元，在分析師的預測範圍內。
